Metabolic signaling mechanisms are increasingly recognized to mediate the cellular response to alterations in workload demand, as a consequence of physiological and pathophysiological challenges. Thus, an understanding of the metabolic mechanisms coordinating activity in the cytosol with the energy-providing pathways in the mitochondrial matrix becomes critical for deepening our insights into the pathogenic changes that occur in the stressed cardiomyocyte. Processes that exchange both metabolic intermediates and cations between the cytosol and mitochondria enable transduction of dynamic changes in contractile state to the mitochondrial compartment of the cell. Disruption of such metabolic transduction pathways has severe consequences for the energetic support of contractile function in the heart and is implicated in the pathogenesis of heart failure. Deficiencies in metabolic reserve and impaired metabolic transduction in the cardiomyocyte can result from inherent deficiencies in metabolic phenotype or maladaptive changes in metabolic enzyme expression and regulation in the response to pathogenic stress. This review examines both current and emerging concepts of the functional linkage between the cytosol and the mitochondrial matrix with a specific focus on metabolic reserve and energetic efficiency. These principles of exchange and transport mechanisms across the mitochondrial membrane are reviewed for the failing heart from the perspectives of chronic pressure overload and diabetes mellitus. (Circ Res. 2014;114:717-729.) 
T he mammalian heart can increase its pump work 3-fold, despite limited capacity to store chemical energy. Changes in energy demand, therefore, require a rapid response from the mitochondria. The size of the total cardiac ATP pool changes little over a wide range of workloads, whereas ATP turnover varies substantially. At high workload, the total ATP pool can turn over in as little as 2 s. 1, 2 As a result, even modest changes in cardiac metabolism can have a significant impact on contractile function. Just as the heart has a large contractile reserve, the heart also has a large metabolic reserve to meet changes in energy demand. This review explores the function and dysfunction of the intracellular mechanisms that transduce the pathophysiological state of the heart to the mitochondria to provide this metabolic reserve.
Heart failure is a syndrome that is characterized by the heart's inability to provide sufficient blood flow to the body. Changes in cardiac metabolism contribute to the organ's impaired contractile function. 3 Here, we discuss 2 models in particular, the hypertrophic heart and the diabetic heart, focusing on the changes in mitochondrial function and how these may contribute to heart failure. Although these 2 pathologies are vastly different in their clinical presentation, the hypertrophic and diabetic hearts share signs of a return to the fetal gene program and impaired metabolic reserve. 4 We discuss potential defects in several parallel pathways that could limit the ability of the failing heart to meet energetic demand. Specifically, we examine the role of intracellular and mitochondrial calcium in regulating mitochondrial metabolism, changes in mitochondrial transporter expression signaling between the mitochondria and the cytosol via intermediate exchange and redox regulation, the mitochondria as signaling organelles, and finally the role of the triacylglyceride pool in regulating mitochondrial function through fuel provision and lipid signaling.
Metabolic Reserve
Metabolic reserve is defined as the available potential energy that is demand accessible in response to an increase in cardiac work. In the hypertrophic heart, increased workload or β-adrenergic stimulation leads to a decrease in the ATP concentration and a reduction in intracellular buffer of ATP and the primary energy buffer in the heart-phosphocreatine (PCr). 5 This, along with findings of restricted fuel utilization, 6 suggests that the metabolic reserve of the hypertrophic heart is reduced, leading Ingwall 7 and Neubauer 8 to speculate initially that the hypertrophic heart is an engine out of fuel.
Metabolic reserve of the heart in diabetes mellitus is less understood and conceptually different from that of hypertrophic heart. In diabetes mellitus, the heart resembles an engine oversupplied with fuel, yet no less restricted in metabolic signaling and the ability to recruit alternative mechanisms of ATP synthesis. Despite an oversupply of energy-rich longchain fatty acids, the heart in diabetes mellitus is energetically compromised in a similar manner to the hypertrophic heart, that is, a decrease in the cellular energy charge, reflected by the relative contents of PCr and ATP. 9 Despite this apparent oversupply, substrates are sequestered into storage pools and are uncoupled from mitochondrial metabolism during the later stages of disease progression into overt heart failure. [10] [11] [12] [13] Consideration of pathological energy starvation invokes the notion of metabolic reserve and efficiency, which becomes disrupted in the hypertrophic and diabetic heart. The efficiency of fuel pathways in the mitochondria exploits conservation of intermediates through metabolic cycles that transform a substrate with little or no change in the cycle's constituents. Cycles have evolved because in a competitive environment the chances for survival are the greatest if resources are used in an optimal way. 14 Steady-state concentrations of cycle metabolites depend on their rates of synthesis and degradation but not on the rate of cycle turnover. [15] [16] [17] [18] In the case of the citric acid cycle (CAC), substrates entering as citrate (as result of the condensation of acetyl CoA and oxaloacetate) do not cause a change in the CAC pool size because the 2 carbons of acetyl CoA are lost as CO 2 in the isocitrate and α-ketoglutarate dehydrogenase reactions, respectively. In contrast, the process of anaplerosis (eg, through the fixation of CO 2 by pyruvate carboxylation) supplies compounds to the CAC through reactions other than citrate synthase ( Figure 1 ). [19] [20] [21] [22] These compounds replenish carbon intermediates lost as amino acids, citrate, or oxaloacetate. 23 By maintaining CAC intermediate levels, anaplerosis facilitates energy transfer in the heart, an organ with high rates of energy turnover. Not surprisingly, changes in CAC flux antedate the functional decline in perfused hearts oxidizing acetoacetate as the sole energy-providing substrate, 24 and the collapse of metabolic cycles in the heart impairs metabolic flexibility and efficiency in the failing heart. 25 Along with this influx of carbon into the cycle, efflux from the CAC intermediate pools also serves to maintain steady-state equilibrium during acute transitions in the individual, linked CAC reaction rates. 17 Under pathological states that induce nonequilibrium conditions, metabolic reserve is challenged. For example, in myocardial ischemia, when glycolysis prevails during the loss of glucose and fatty acid oxidation because of the lack of oxygen, the collapse of cycles becomes detrimental to conserving pathways and thus metabolic efficiency.
Ca 2+ as a Metabolic Regulator
Extensive investigations have attempted to identify the key second messaging components that link mitochondrial respiration and cardiac demand. Although several candidates have been proposed, Ca 2+ release by the sarcoplasmic reticulum (SR) now seems as a central player in modulating the metabolic rate of the heart in response to changes in energetic demand. 26, 27 Figure 1 depicts Ca 2+ entry into mitochondria and the mechanisms, whereby Ca 2+ modifies mitochondrial metabolism. Ca 2+ enters the mitochondria through the recently identified mitochondrial calcium uniporter, 28 a low affinity calcium transporter. Ca 2+ entry through mitochondrial calcium uniporter is driven by the membrane potential across the inner mitochondrial membrane (IMM) 29 and therefore dependent on electron transport chain (ETC) activity and mitochondrial metabolism. The regulation of mitochondrial calcium uniporter activity has yet to be fully elucidated, especially in heart failure; however, mitochondrial calcium uptake 1 gates Ca 2+ entry through mitochondrial calcium uniporter, preventing Ca 2+ overload and maintaining a wide dynamic range for Ca 2+ entry into the mitochondria. 30, 31 Mitochondria are present in close proximity to the ryanodine receptors of the SR, and large localized increases in Ca 2+ in these microdomains facilitate sufficient mitochondrial Ca 2+ entry. 26 Mitofusin2 is integral in bringing the mitochondria and the SR into close communication. 32 The loss of mitofusin2 severely limits mitochondrial Ca 2+ uptake. 32 These observations highlight the importance of viewing mitochondria not in isolation but within the context of the intact cell. The total flux of Ca 2+ across the IMM remains unknown; however, a range of estimates in the literature has been reported, ranging from 10 nmol/L to 26% of total SR calcium load. 33, 34 Until this issue is resolved, modeling of mitochondrial dynamics remains difficult in isolation from appropriate calcium buffering concentrations.
Ca 2+ influences flux through competing pathways of mitochondrial metabolism, while also maintaining relative balance through the activation of calcium-dependent-dehydrogenases 17, 35 (Figure 1 ); pyruvate dehydrogenase (PDH) catalyzes the conversion of pyruvate to acetyl CoA, and the rate-limiting enzymes of the CAC, isocitrate dehydrogenase, and α-ketoglutarate dehydrogenase. In addition, Ca 2+ controls the efflux of CAC intermediates out of the mitochondria and shifts the efflux/oxidation ratio toward oxidation and continued formation of reducing equivalents. 17 to changes in either intracellular Ca 2+ or dehydrogenase enzyme-substrate K m , via altered mitochondrial pH, on coordinating flux through the first and second spans of the CAC. This study, combining data from isolated hearts and isolated mitochondria, elucidated a conceptual framework of Ca 2+ activation of the intramitochondrial dehydrogenases linking flux through the CAC with intermediate exchange with the cytosol through NADH-dependent exchange mechanisms across the mitochondrial membrane. NADH-dependent exchange is described in Figure 1 and occurs through the malate/aspartate shuttle. The view that emerges from this framework is that of a homeostatic mechanism that transduces the physio-metabolic state of the cardiomyocyte to a pivot point between the first and second spans of the CAC, α-ketoglutarate dehydrogenase. The implication being that Ca 2+ decreases α-ketoglutarate efflux out the mitochondria. The other component of the malate/ aspartate shuttle is the aspartate/glutamate carrier that is activated by Ca 2+ . 36 Ca 2+ seems to decrease net CAC intermediate loss to the cytoplasm, whereas increasing the rate of intermediate exchange across the mitochondrial membranes. Any Ca 2+ -dependent coordination of cardiac demand and mitochondrial metabolism suggests that matrix calcium is modified in a beat-to-beat manner. There is indeed emerging evidence for such beat-to-beat changes in mitochondrial Ca 2+ . 35, [37] [38] [39] Rapid Ca 2+ transients, faster than the change in bulk Ca 2+ in the cytosol, have been measured in the mitochondria of isolated cardiomyotes, 38 supporting the idea of a Ca 2+ microdomain. The transients peak much earlier than in the bulk cytosol, whereas decay is much slower.
Mitochondrial Ca 2+ in Heart Failure
Both the hypertrophied heart and the heart in diabetes mellitus are characterized by alterations in Ca 2+ signaling and change in SR Ca 2+ dynamics. 40, 41 The hypertrophied heart is characterized by a decrease in SR Ca 2+ load and an increase in cytoplasmic Na + levels. 37, 41 The Na + /Ca 2+ exchanger mediates Ca 2+ efflux out of the mitochondria, and an increase in cytoplasmic Na + limits the size of mitochondrial Ca 2+ transient. 37, 42 Here, it is important to remember that a reduction in CAC-derived reducing equivalents (NADH) affects not only the generation of ATP but also the ability of the cardiomyoctye to buffer reactive oxygen species. NADPH, a key cofactor in H 2 O 2 elimination, is oxidized to NADP + during H 2 O 2 reduction. Mitochondrial NADH serves to replenish the NADPH pool through transhydrogenation. 37 In the failing heart, there is a reduction in NADH formation, which affects ATP production but would also reduce antioxidant defenses. The decrease in Ca 2+ loading of the SR is partially because of a decrease in expression of the ATP-dependent SR Ca 2+ pump expressed in the heart (SR Ca 2+ -ATPase [SERCA2a]). 43, 44 Increasing the Figure 1 . Calcium regulation of mitochondrial metabolism. Calcium (Ca 2+ ) released by the sarcoplasmic reticulum is taken up by the mitochondria via the mitochondrial calcium uniporter (MCU). Mitochondria are found in close association with the calcium release channels in the sarcoplasmic reticulum, the ryanodine receptors (RyR), creating a Ca 2+ microdomain. Mitofusin2 (Mfn2) acts to bring the mitochondria and sarcoplasmic reticulum (SR) into close communication. Ca 2+ activates (designated by the dashed purple lines) mitochondrial metabolism by increasing the activities of pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (ICDH), and αketoglutarate (α-KG) dehydrogenase (α-KDH) resulting in increased metabolism of pyruvate and fatty acyl CoA and increased NADH formation. Ca 2+ also increases the exchange rate of malate/aspartate (Malate/ASP) shuttle by increasing the activity of the ASP/glutamate (GLUT) exchangers 1 and 2 (AGC1/2), while inhibiting (indicated by the dotted red line) net efflux of citric acid cycle (CAC) intermediates out of the mitochondria via the oxaloacetate (OAA)/malate cotransporter (OMC). The malate/ASP shuttle is responsible for maintaining the cytoplasmic NAD + pool. The 2 spans of the CAC are indicated by blue (reductive span) and green (oxidative span) lines. Pyruvate can feed into the reductive span through PDH or feed into OAA and malate pools in the oxidative span via anaplerotic flux. Ca 2+ is cleared from the mitochondrial matrix by the actions of the Na + /Ca 2+ exchanger (NCX). The magnitude of the calcium release by the SR is dependent on the actions of SR Ca 2+ -ATPase (SERCA2a), which facilitates Ca 2+ reuptake into the SR (illustration credit: Ben Smith). FA-CoA indicates fatty acyl-carnitine. February 14, 2014 expression of SERCA2a through gene therapy has shown the potential to mitigate some of the contractile dysfunction in the hypertrophied heart 45, 46 ; however, the underlying metabolic defects are not corrected and therefore the delivery of ATP for SERCA remains impaired, which has lessened the positive effects of increasing SERCA expression in some studies. 47, 48 In the diabetic heart there is an increase in diastolic [Ca 2+ ] that is also partially mediated by a reduction in SERCA2a activity. 40 There is also evidence that the SR calcium load is decreased. 49 Overexpression of SERCA2a in the heart from diabetic animals is associated with improved contractile function 50 ; however, mitochondrial Ca 2+ transients and their impact on cardiac metabolism have not yet been studied in the heart of diabetic individuals. Figure 2 illustrates the energy transfer system within the cardiomyocyte. The diffusion of ATP and ADP is limited in the cell and therefore alternative mechanisms of transfer are required. Much of this transfer is accomplished via the creatine kinase (CK) system. 51 CK transfers the phosphoryl groups from ATP to PCr at a rate that is 10× faster than the rate of ATP synthesis by mitochondrial metabolism. 52 Classically, this shuttle mechanism was thought to facilitate much of the energy transfer between the mitochondria and the sites of utilization. However, recent work has shown that a significant reduction in the capacity of this system, either through loss of CK expression or a decrease in available creatine, does not impair significantly cardiac function under basal conditions. [53] [54] [55] In addition, under severe metabolic inhibition, direct ATP transfer seems to replace the CK shuttle as the primary energy transfer system. 54 Just as microdomains exist between the tight junctional contacts of the mitochondria and the SR, interactions between the mitochondria and sights of ATP utilization (ie, MgATPases) regulate energy transfer. The CK null mouse undergoes mitochondrial reorganization that seems to reduce the diffusion distances between the mitochondria and the sites of utilization. 51 Cytoskeletal mutations, which disrupt the structural organization of mitochondria within the cell and result in diffuse organization of mitochondria within the heart, affect energy transfer and change in the apparent K m of ADP for ATP synthesis. 56, 57 The latter point is of experimental significance and suggests, once again that isolated mitochondria behave much differently even than mitochondria in permeabilized cells. Not only does organelle localization minimize perfusion distances, but it also seems to affect enzyme activities/affinities significantly. 56 Measurements of ATP turnover in vivo are technically challenging and therefore the relative importance of the different phosphate transfer systems needs further investigation. Magnetic resonance spectroscopy-based methods have been used successfully to measure ATP flux via CK (ATP↔PCr) in vivo 58, 59 ; however, measuring ATP turnover or direct ATP Figure 2 . Phosphotransfer systems in the heart. ATP is formed within the mitochondria by ATP synthase, which uses the proton gradient across the inner mitochondrial membrane (IMM) to catalyze ATP formation from ADP and Pi (not depicted). The proton gradient is generated by actions of the electron transport chain (shown as complexes I-IV) after donation of an electron by NADH at complex I. Once formed ATP can cross the IMM via the adenine nucleotide transporter (ANT). ANT also brings ADP into the mitochondria from the cytoplasm. The energy contained within ATP is then transferred to the cytoplasmic phosphocreatine (PCr) pool through the actions of a mitochondrial isoform of creatine kinase (CK). PCr is less diffusion limited than ATP and is therefore an efficient means of transmitting energy to the peripheral sites of ATP utilization, depicted as sarcoplasmic reticulum (SR) Ca 2+ -ATPase (SERCA2a)-dependent calcium reuptake by the sarcoplasmic reticulum and myosin ATPase-dependent cross-bridge cycling within the sarcomere. PCr is converted back to free creatine (Cr) by cytoplasmic CK with the freed energy used for ATP formation and driving the peripheral ATPases. An alternative phosphotransfer pathway (depicted by a dashed line) is for ATP to directly travel from the mitochondria to the sites of utilization independent of the PCr:CK system. As ATP is diffusion limited, the direct transfer of ATP from the mitochondria to a site of utilization requires close localization between the mitochondria and the peripheral ATPase (illustration credit: Ben Smith). transfer (ATP↔ADP+Pi) is problematic. Direct measurement of ATP turnover (ATP↔ADP+Pi) requires that the Pi peak can be visualized clearly on a magnetic resonance spectrum. The level of Pi in the heart is low and the peak attributed to Pi overlaps with the much larger peak for 2,3-disphosphoglycerate, a product glycolytic metabolism generated by erythrocytes. Recent work by Zhang and colleagues 59, 60 has pioneered an approach to measure ATP turnover indirectly by measuring total ATP utilization and subtracting out the measurable component that can be attributed to ATP flux via CK. As will be discussed below, methodologies like these that try to quantify energy transfer/turnover in the intact heart are essential as static levels of metabolites have proven ineffective in adequately describing the energetic status of the failing heart. 58
Energy Transfer

Energy Transfer in Heart Failure
The complete notion of the failing heart as an engine out of fuel was challenged by the creatine-deficient mouse in which the PCr pool was almost completely abolished. 53 This mouse model did not show differences in contractile function after myocardial infarction. This led the authors to question whether the failing heart was indeed out of fuel. A follow-up study, however, showed that the mitochondrial organization was unchanged in this model 55 and suggests that the tight coupling between the mitochondria and the sites of utilization was maintained, potentially allowing for direct exchange of ATP and ADP between the sites of utilization and the sites of generation to compensate for the loss of CK shuttle.
In the hypertrophied heart, there is initially a decline in PCr pool before any changes in ATP. 61, 62 The decline in PCr is the result of a decrease in total creatine, 63 with the decline in total creatine directly related to the severity of heart failure. 64 As the heart moves closer to decompensation, both the PCr and ATP pools begin to decline. 65 An important consideration is that even in late failure the concentration of ATP never falls below the K m of ATP for the ATPase, 63 further highlighting the need for understanding ATP turnover (and not ATP content) as well as localized (rather than global) changes in metabolite concentrations. Even indexing PCr:ATP can fail to uncover the degree of energetic deficit in the failing heart. Left ventricular hypertrophy alone is associated with a reduction in the PCr:ATP; however, there is not a further decline in the PCr:ATP in patients that have transitioned to chronic heart failure. 58 There is, however, a significant decline in CK flux between left ventricular hypertrophy and chronic heart failure. 58 Therefore, at a similar PCr:ATP, the delivery of energy via CK can be dramatically different. Interaction between mitochondria and myofibrils is reduced in heart failure, significantly reducing the capacity of direct ATP/ADP transfer between the mitochondria and the sites of utilization. 66 Less is understood about the phosphotransfer system of the heart in diabetes mellitus, especially in hearts from individuals who also present with obesity. The PCr:ATP is decreased in hearts from type 2 diabetic individuals, 9 whereas other studies have suggested no change in PCr:ATP under basal conditions in type 1 diabetic hearts. 67
Mitochondrial Metabolite Transporters
Key metabolite transport proteins regulate substrate entry across outer and IMMs. We will now review the entry of fatty acids and pyruvate into the mitochondria and how heart failure modifies these processes (illustrated in Figure 3 ).
Fatty Acids
Long-chain acyl coenzyme A synthetase isoform 1 catalyzes the synthesis of acyl coenzyme A from long-chain fatty acids in the heart. 68 Acyl CoA synthetase isoform 1 is expressed on the mitochondrial membrane. 68 Hearts from mice lacking cardiac acyl CoA synthetase isoform 1 undergo hypertrophy, most likely because of increased glucose 6-phosphate activation of the mammalian target of rapamycin. 69 The ratelimiting step in fatty acid oxidation is the transport of fatty acids across the mitochondrial membrane. 70 Carnitine palmitoyltransferase 1 (CPT1), located on the outer mitochondrial membrane (Figure 3 ), controls the entry of fatty acids into the mitochondria by catalyzing acyl transfer from CoA to carnitine. The heart expresses 2 isoforms of CPT1, muscle and, to a lesser extent, liver (l-CPT1). L-CPT1 is the primary isoform expressed in the neonatal heart when glucose metabolism predominates, whereas muscle CPT1 dominates in adulthood. 71 The activity of CPT1 is inhibited by the concentration of malonyl CoA in vitro; however, the in vivo relationship between the concentration of malonyl CoA and CPT1 activity is more complicated. The IC 50 for muscle CPT1 inhibition by malonyl CoA is much lower than the intracellular concentration of Figure 3 . Protein transporters regulate metabolic substrate entry into the mitochondrial matrix and control the relative rates of oxidative metabolism. Fatty acyl CoA (FA-CoA) and pyruvate enter the mitochondria through protein transporters. FA-CoA is first converted to fatty acyl-carnitine (FA-carnitine) by carnitine palmitoyltransferase 1 (CPT1) located on the outer mitochondrial membrane (OMM). CPT1 activity is controlled by the concentration of malonyl CoA and therefore the activities of malonyl CoA decarboxylase (MCD) and acetyl CoA carboxylase 2 (ACC2) indirectly regulate CPT1 activity. FA-carnitine enters the mitochondria via carnitine-acylcarnitine translocase where it is then converted back to FA-CoA by CPT2 located on the inner mitochondrial membrane (IMM). FA-CoA is then able to undergo oxidation within the mitochondria to yield acetyl CoA for the citric acid cycle (CAC). Pyruvate enters the mitochondria via the newly discovered mitochondrial pyruvate carriers 1 and 2 (MPC1 and MPC2) protein complex. Pyruvate is then converted to acetyl CoA by the actions of pyruvate dehydrogenase (PDH). Acetyl CoA exerts product inhibition on the activity of PDH. CACT indicates carnitine-acylcarnitine translocase.
malonyl CoA, 72, 73 suggesting that CPT1 would be largely inhibited under normal conditions. This is contrary to the known preference of the adult heart for fatty acid oxidation. A recent study by Smith et al 73 in skeletal muscle suggests that the IC 50 for malonyl CoA inhibition of CPT1 is an order of magnitude greater in permeabilized muscle fibers compared with isolated mitochondria, and the IC 50 increases with increased palmitoyl CoA concentration. This work suggests that high intracellular levels of fatty acyl CoA can compete with malonyl CoA to reduce CPT1 inhibition and may require us to re-evaluate how we interpret steady-state levels of malonyl CoA.
The concentration of malonyl CoA in the heart is regulated by 2 competing enzymes: acetyl CoA carboxylase 2 (ACC2) catalyzes the conversion of acetyl CoA to malonyl CoA, whereas malonyl CoA decarboxylase decarboxylates malonyl CoA to acetyl CoA. 74, 75 Mice deficient in ACC2 display a significant increase in fatty acid oxidation, 76 whereas mice deficient in MCD show reduced rates of fatty acid oxidation and increased rates of glucose utilization. 75 In failing hearts, the relationship between CPT1 activity and malonyl CoA is also becoming more complex than was previously appreciated. The ACC2-deficient mouse is protected from some of the metabolic remodeling after aortic banding, and this correlates with a reduction in malonyl CoA levels and an increase in fatty acid oxidation. 76 However, the expression of l-CPT1 is significantly increased in the hypertrophied heart. 77 L-CPT1 expression itself induces reduced fatty acid oxidation in whole hearts, 78 independent of changes in malonyl CoA levels; a curious finding considering that l-CPT1 is much less sensitive to malonyl CoA inhibition. 72 In the diabetic heart, increased fatty acid oxidation is associated with elevated malonyl CoA. 79 The elevated fatty acyl CoA content of diabetic hearts may lessen the impact of malonyl CoA on CPT1 activity.
The total CPT1 activity is decreased in the hypertrophied heart, 77 which is in agreement with a decrease in the mitochondrial metabolism of fatty acids. Studies in mice with either deficient muscle CPT1 to limit fatty acid oxidation 80 (although with uncertain responses in the l-CPT1 isoform expression) or ACC2 knockout, 76 to promote fatty acid oxidation, suggest that decrease in fatty acid oxidation in the hypertrophic heart is a maladaptive response. In diabetes mellitus, the heart shows no change in CPT1 activity at a time point where there is an observable increase in fatty acid oxidation, 79 indicating that at least in the diabetic heart the delivery of substrates to the mitochondria, rather than the activity of the transport system across the mitochondria, is a more important determinant of fatty acid oxidation.
Pyruvate
Pyruvate is the penultimate intermediate of the glycolytic pathway in the cytosol under aerobic conditions. The metabolism of pyruvate by the mitochondria is illustrated in Figure 3 . Recent work has identified 2 proteins that are important components of the long sought after pyruvate transporter: mitochondrial pyruvate carriers 1 and 2. 81 Their expression was sufficient to promote pyruvate uptake in a model system, and mutations were identified in families displaying a significant impairment in pyruvate oxidation. How these proteins are affected in heart failure is a point to consider and further investigate. After transport into the mitochondria, pyruvate is converted to acetyl CoA by the PDH complex, feeding into the CAC. The CAC represents the convergence point for all oxidative metabolism, including glucose and fatty acids, with the acetyl CoA formed during β-oxidation also entering the CAC. Any distinction between acetyl CoA derived from these separate sources remains unknown, and none has been demonstrated. 82, 83 In both the hypertrophied heart and the heart in diabetes mellitus, the rate of pyruvate metabolism is reduced relative to the glycolytic rate. 22, 77, 84 In both pathologies increasing flux through PDH has positive effects on reversing both the metabolic and contractile remodeling. 22, 85 Pyruvate provision itself has positive inotropic effects in the heart and improves cardiac function in patients with heart failure. 86, 87 Some of this effect can be traced to increased ATP generation through increased flux of pyruvate through the CAC, but an additional direct effect on the ryanodine receptors has also been suggested. 88 Pyruvate seems to minimize increases in diastolic calcium by inhibiting SR Ca 2+ release.
In diabetes mellitus, the heart exhibits an increased reliance on fatty acid metabolism, and upregulation of fatty acid utilization limits the metabolism of pyruvate. This occurs, in part, because of the fatty acid-induced expression of PDH kinase through increased peroxisome proliferator-activated receptor (PPAR)α activation. [89] [90] [91] [92] In the hypertrophied heart, the oxidation of pyruvate, as a glycolytic product, is mismatched to the elevated rate of glycolysis, which could potentially lead to a buildup of glycolytic intermediates (including lactate) in the cytoplasmic compartment. This mismatch of glycolysis and glucose oxidation is accounted for by elevated pyruvate carboxylation to form malate. 50, 69 The hypertrophic heart works to maintain CAC flux by upregulating anaplerosis (described in Metabolic Reserve and Figure 1 ). In the hypertrophied heart, the elevated anaplerotic flux occurs via carboxylation of pyruvate through increased expression of the NADPH-dependent, cytosolic malic enzyme-1. 22 The consequences of shifting 1 pyruvate molecule from oxidation to anaplerosis reduces ATP generation from 14 to 3 ATP. Anaplerotic entry into the second span of the CAC bypasses several of the NADH-generating reactions. In addition, the carboxylation of pyruvate to form malate via malic enzyme-1 consumes and depletes NADPH. The reduction in NADPH may represent one of the mechanisms responsible for the reduced triacylglyceride content within the hypertrophic myocardium. 22, 93 
Uncoupling Protein 3
Uncoupling protein 3 (UCP3) was originally proposed to act as an uncoupler of mitochondrial metabolism by dissipating some of the proton gradient across the IMM and preventing reactive oxygen species formation. 94, 95 However, more recent evidence suggests that UCP3 acts as a fatty acid ion carrier, providing an overflow pathway when fatty acids accumulate within the mitochondria and buffering the mitochondrial concentration of CoA. 96, 97 More significantly, our understanding as to whether UCP3 expression is a positive adaptive response to help maintain fatty acid oxidation within the mitochondria or maladaptive is also changing. The induction of UCP3 during ischemia in insulin-resistant rat hearts improves recovery and increases fatty acid oxidation while also increasing cardiac efficiency. 97 The latter point argues against UCP3 inducing uncoupling of ETC flux from ATP synthesis. In addition, ischemia results in a greater decrease in myocardial ATP levels in the UCP3 null mouse. 98 This further supports the emerging realization that UCP3 expression is positive in the heart and may not be related to reactive oxygen species production as previously envisioned. Thus, revisiting some of the past observations concerning heart failure and UCP3 expression may be necessary. 99, 100 
Coordinating Metabolic Compartments via Intermediate Exchange Across the Mitochondrial Membrane Acetyl CoA
The concentrations of acetyl CoA, in both mitochondria and cytoplasm, have a significant impact on metabolic rates and mitochondrial fuel selection. In addition, as discussed later, nuclear acetyl CoA levels can exert significant control over gene expression through post-translational modification of proteins. As mentioned in Mitochondrial Metabolite Transporters, the cytoplasmic pool of acetyl CoA is thought to originate from exchange of the CAC intermediate citrate. 83, 101, 102 Figure 4 illustrates the sources of cytoplasmic acetyl CoA. The primary mechanism whereby intramitochondrial acetyl CoA levels are buffered occurs through the actions of carnitine acetyltransferase (CAT), which controls the mitochondrial acetyl CoA concentration by shunting acetyl CoA to acetyl carntine. 103, 104 CAT helps to maintain the mitochondrial CoA pool and reduces product inhibition by mitochondrial acetyl CoA accumulation (Figure 4 ). In addition, as will be discussed in Mitochondrial Contribution to Post-Translational Modification of Proteins, preventing the accumulation of acetyl CoA could have beneficial effects in heart failure as it would lead to reduced acetylation of the mitochondrial proteome. Acetyl carnitine, unlike acetyl CoA, can be exported out of the mitochondria and either re-enter the mitochondrial acetyl CoA pool or be exported out of the cell. 104 Acetyl carnitine does not seem to contribute to the cytoplasmic acetyl CoA pool nor to participate in malonyl CoA formation and CPT1 inhibition. 104 After adrenergic challenge, pyruvate incorporation into acetyl carnitine is reduced, as acetyl CoA is fully metabolized in response to increased ATP demand. 103 The acetyl carnitine pool represents a previously unappreciated metabolic reserve within the heart. A muscle-specific CAT null mouse was created recently, and the results suggest an alternative mechanism describing the metabolic inflexibility in heart failure. 104 With this mechanism, contrasting regulation via the Randle cycle, 105, 106 the ability of pyruvate to inhibit fatty acid oxidation was reduced by CAT loss, and the muscle-specific loss of CAT leads to glucose intolerance. Re-expressing CAT restored the capacity of pyruvate to inhibit fatty acid oxidation; however, this inhibition was independent of changes in CPT1 activity. CAT maintains metabolic flexibility by allowing for uninterrupted CAC flux and metabolite clearance irrespective of ETC activity through direct competition of glucose and fatty acid-derived acetyl CoA for entry into the CAC. Carnitine deficiency has been documented in heart failure 107, 108 and pressure overload hypertrophy specifically. 109 Supplementation with carnitine has improved cardiac function, 110 although a metabolic reason for this effect is just now being elucidated. Initially, the carnitine deficit was thought to be limiting for fatty acyl CoA entry into the mitochondria, but now such deficiency is known to limit the buffering capacity for acetyl CoA levels within the mitochondria. 104 Figure 4 . Intermediate exchange across the mitochondrial membrane buffers the cytoplasmic and mitochondrial acetyl CoA concentrations. The concentration of acetyl CoA formed during both pyruvate and fatty acyl CoA (FA-CoA) oxidation is buffered within the mitochondrial matrix by carnitine acetyltransferase (CAT). CAT converts acetyl CoA to acetyl carnitine. Acetyl carnitine can then be exported out of the mitochondria by carnitine-acylcarnitine translocase and potentially be cleared from the cell into the circulation or re-enter the mitochondria to undergo oxidative metabolism. Cytoplasmic acetyl CoA does not originate from mitochondrial acetyl CoA but rather from citric acid cycle (CAC) intermediate citrate, which is converted to acetyl CoA via ATP citrate lyase (ACL). Partial oxidation of FA-CoA in the peroxisome has also been suggested to contribute to the cytoplasmic acetyl CoA pool. The activities of malonyl CoA decarboxylase (MCD) and acetyl CoA carboxylase 2 (ACC2) regulate the ratio of cytoplasmic acetyl CoA to malonyl CoA. CACT indicates carnitine-acylcarnitine translocase; IMI, inner mitochondrial membrane; and OMM, outer mitochondrial membrane. February 14, 2014 NAD + /NADH+H + The NAD + /NADH ratio can influence cardiac metabolism at several levels. 111 Flux through glycolysis is regulated by the NAD + /NADH ratio via the activity of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and lactate dehydrogenase. NAD + is reduced to NADH by GAPDH, and NADH must be continually reoxidized to NAD + in the mitochondria to maintain glycolytic flux. The IMM is impermeable to pyridine nucleotides and therefore alternative mechanisms have been devised to transfer reducing equivalents between the cytoplasmic and mitochondrial environments. 112 The primary mechanism in the heart is the malate-aspartate shuttle 113 discussed in Ca 2+ as a Metabolic Regulator (Figure 1 ). The challenge of pressure overload leads to an initial increase in NADH shuttling, which returns to baseline levels after the development of compensated hypertrophy and elevates again on decompensation of the hypertrophied myocardium. 114 The rate of NADH shuttling is proportional to the coupling of glycolysis and glucose oxidation, with glycolysis increasing rapidly with the induction of hypertrophy with proportionally, less of an increase in glucose oxidation at pyruvate dehydrogenase, in part, because of elevated malic enzyme activity. 77, 114 The ratio of NAD + /NADH influences intramitochondrial substrate metabolism by regulating flux through the PDH complex (glucose) and CAC flux through the regulation of dehydrogenases within the CAC (glucose and fatty acids). In addition, the NAD+/NADH ratio may also influence ETC activity. There are also nonmetabolic effects of the NAD+/NADH ratio. SR calcium load is reduced when the cytoplasmic concentration of NADH is increased, and this seems to be mediated with a reduction in SERCA2a activity. 115 NAD + levels are reduced in failing heart possibly because of the downregulation of nicotinamide phosphoribosyltransferase, 116 the rate-limiting enzyme in NAD + salvage pathway. Nicotinamide phosphoribosyltransferase expression is decreased by pressure overload and nicotinamide phosphoribosyltransferase overexpression improves metabolic recovery after myocardial infarction. 116 Recent data highlight a potential role for changing NAD + levels to affect post-translational modifications in the failing heart. 117, 118 
Mitochondrial Contribution to Post-Translational Modification of Proteins
Lysine acetylation is now recognized as a significant modifier of nonhistone proteins within the nucleus, the myofilament and mitochondria that rival protein phosphorylation in terms of the number of targets modified and the significance to cellular function. 119 The level of lysine acetylation is a balance between the rate of acetylation by histone acetyl transferases and deacetylation by histone deacetylases (HDACs) named after their initial identification in histone modification. Recent in vitro studies have also suggested that nonenzymatic processes may contribute to lysine acetylation, especially within mitochondria. 120 Lysine acetylation regulates gene transcription targets and non-nuclear protein targets that are responsible for cardiomyocyte growth and cardiac remodeling, cardiac metabolism, reactive oxygen species buffering, and cardiac contractility. 119 In a recent undertaking Foster et al 119 tried to characterize the total cardiac acetyl-lysine proteome in guinea pig hearts. The majority of acetylated proteins were identified in the mitochondria, with the majority of nonmitochondrial acetylation sites in the sarcomere and cytoskeletal proteins. The significance of these modifications on protein function still requires classification. However, protein acetylation highlights the significant impact that mitochondrial metabolism holds on the cardiac proteome through the production of acetyl CoA.
Histone Acetyl Transferases and Heart Failure
The transcriptional co-activator CREB-binding protein and p300 display histone acetylation activity and have been shown to be integral in the development of cardiac hypertrophy in response to chronic phenylephrine treatment or after myocardial infarction. 121, 122 Overexpression of CREB-binding protein or p300 induces cell remodeling and hypertrophy and these changes are dependent on acetylase activity. 121 Both CREB-binding protein and p300 are extramitochondrial histone acetyl transferases. GCN5L1 was identified recently as an acetyltransferase, capable of localizing to the mitochondria in various cells lines, that may mediate acetylation of the mitochondrial proteome. 123 A role for GCNL51 in cardiac mitochondria still needs to be investigated. Others have suggested that a significant portion of mitochondrial acetylation could be nonenzymatic. 120 Incubating isolated heart or liver mitochondrial proteins in a model environment meant to recapitulate the environment of the mitochondrial matrix induces extensive protein acetylation in the presence of acetyl CoA. The level of acetylation was unaffected by previously denaturing the mitochondrial proteins or increasing the concentration of CoA, both of which should reduce the activity acetyltransferases. Under diseased states in which acetyl CoA accumulates within mitochondria, nonenzymatic acetylation could become significant.
HDACs and Heart Failure
A great deal more research has been done on the impact of HDACs on cardiac function and heart failure. The HDACs are a varied class of enzymes that display both detrimental and positive effects on cardiac function. 124 The sirtuins, specifically sirtuin1 (Sirt1) and sirtuin3 (Sirt3), are class III HDACs that are generally thought to be cardiac protective and exert significant control over cardiac metabolism. 118, 124, 125 Sirt1 is thought to localize to the nucleus and controls gene transcription through both histone and nonhistone deacetylation. Sirt3 is found in the mitochondria and regulates cardiac metabolism and mitochondrial fuel selection. The activity of Sirt3 is increased by caloric restriction, and the deacetylation of mitochondrial proteins is a key event of the cardio-protective effects of caloric restriction. 126 The class III HDACs coordinate metabolic rates with protein function as their activities are dependent on NAD + and their actions are opposed by the production of acetyl CoA. In contrast, the class I and class II HDACs are zinc-dependent and therefore represent less of an integrative control system between cardiac metabolic rates and protein function. 127 In heart failure there is a decrease in NAD + and increased mitochondrial protein acetylation, whereas NAD + supplementation reduces the level of acetylation and prevents some of the hypertrophic remodeling. 117, 128 Inhibiting complex I of the ETC in mouse hearts through genetic knockdown of one of the subunits of complex I reduced NADH oxidation and the NAD + /NADH ratio and increased mitochondrial protein acetylation and sensitivity to hypertrophic remodeling after pressure overload. 129 Therefore, not only is the absolute level of NAD + important in regulating Sirt3 activity, so too is the ratio of NAD + /NADH. Surprisingly, even stimuli that normally induce physiological hypertrophy lead to pathological remodeling when protein acetylation is increased by inhibiting complex I. 129 This suggests that one of the factors that differentiate pathological from physiological hypertrophy could be the activity of Sirt3. This is in agreement with a previous study that demonstrated that physiological hypertrophy leads to a larger increase in total Sirt3 expression than does pressure overload or chronic isoproterenol infusion. 130 A model emerges of acetylation acting as a break when rates of acetyl CoA formation exceed oxidative metabolism, whereas Sirt3 acts in opposition to maintain CAC flux as acetyl CoA increases. Just as in any biological system, a balance between such opposing forces is most likely required to prevent metabolic dysfunction.
Metabolic Signals as Atrophic and Hypertrophic Remodelers
Thus far, we have discussed adaptive responses in mitochondrial metabolism and how they may contribute to the observed limitation in metabolic reserve in the failing heart.
What is also possible is that some of the metabolic changes that occur in the development of heart failure could mediate the hypertrophic remodeling. Although we have discussed the heart in diabetes mellitus as being pathogenically different pathology from the hypertrophied heart, there is an emerging realization that diabetes mellitus and obesity can result in hypertrophic remodeling even in normotensive patients or animal models of diabetes mellitus. 131, 132 Because the diabetic heart is characterized by an oversupply of nutrients, a concept that emerged was the induction of hypertrophy was because of an increase in metabolic load. 133 In animal models of diabetes mellitus, the use of thiazolidinediones and other nonthiazolidinediones results in improved circulating substrate milieu and a reversal of both cardiac metabolism and contractile function. 10, 11 In models of hypertrophy, changing mitochondrial metabolism has led to reduced left ventricular remodeling and hypertrophy, suggesting that mitochondrial activity can also exert some control over hypertrophy and atrophy. As an example, the knockdown of ACC2 prevents much of the hypertrophic remodeling in response to pressure overload by preventing the classic substrate switching observed in the hypertrophic heart. 76 As we have already discussed, the sirtuins may play a role in this capacity. An additional candidate for integrating the metabolic and growth signals in response to mitochondrial metabolism is the nutrient sensor AMP kinase. 134, 135 Signaling through AMP kinase has been shown to regulate protein degradation through E3 ligases. 134 Pressure-overload hypertrophy and diabetes mellitus induce increased flux of glucose through the hexosamine biosynthesis pathways, generating O-linked N-acetylglucosamine. Inhibiting O-linked N-acetylglucosamine accumulation reduces hypertrophic remodeling and heart failure. 136, 137 Although studies such as these are in their infancy, 138 changes in mitochondrial metabolism observed in the failing heart may not be simply maladaptive responses that are induced by structural changes, but rather mediate the structural changes. 139 Figure 5 . Turnover of long-chain fatty acids (LCFAs) within the myocardial triacylglyceride (TAG) pool and their importance in myocardial signaling. LCFAs, found within the circulation either complexed to albumin or esterified into triacylglyceride rich lipoproteins (TG-lipoprotein), enter the cell via a protein-mediated mechanism across the sarcolemma that is sensitive to CD36 expression. The insulin sensitive fatty acid transport protein 1 (FATP1) and the cardiac-specific FATP6 have also been implicated in LCFA uptake by the heart; however, at present only a direct effect of CD36 expression on TAG dynamics has been demonstrated. 140 Lipoprotein lipase (LPL) is required to liberate LCFA from their esterified form in TG-lipoprotein. After entry into the myocyte LCFA can either enter the mitochondria for oxidation or cycle through the TAG pool (TAG turnover). TAG turnover is defined by the diacylglycerol acyltransferase 1 (DGAT1) dependent on rate (esterification) and the adipose triglyceride lipase (ATGL) dependent on off rate (lipolysis). After LCFA cycling through the TAG pool, LCFA can then be transported into the mitochondria for oxidation or used to initiate gene transcription via peroxisome proliferator-activated receptor α (PPARα). LCFA must first be cycled through the TAG pool to efficiently activate gene transcription. February 14, 2014
Triglycerides as a Source of Signaling Molecules
The myocardial triacylglyceride pool was initially viewed as an inert storage depot; however, recent work has identified the triacylglyceride pool as a dynamic organelle within the heart that provides key signaling molecules for the regulation of myocardial metabolism 140, 141 while buffering the intracellular availability of fatty acids for oxidation. 142 Figure 5 illustrates the key role played by the triacylglyceride pool in regulating PPARα activity. PPARα controls the expression of many of the regulatory enzymes responsible for fatty acid oxidation in the heart, 143 with increased PPARα expression coinciding with increased fatty acid utilization. 90, 144 It was shown recently that fatty acids liberated from the triacylglyceride pool by the actions of adipose triglyceride lipase are required to activate PPARα signaling. 141 Cardiac-specific loss of adipose triglyceride lipase expression prevents PPARα activation in the heart and suggests that fatty acids must first be esterified into the triacylglyceride pool to signal through the PPARα as fatty acid uptake was not impaired in this model. Following up on this work, we have determined that the uptake of fatty acids into the cell and the turnover of fatty acids within the triacylglyceride pool are reciprocally regulated. 140 This ensures that the uptake of fatty acids and triacylglyceride turnover are proportional so that rates of fatty acid uptake and mitochondrial metabolism are appropriately matched. In heart failure, there is dysregulation in triacylglyceride turnover. In the hypertrophic heart we have shown that triacylglyceride turnover is decreased, and this decrease is a key limitation in substrate provision to the mitochondria. 93 A decrease in myocardial adipose triglyceride lipase activity exacerbates the hypertrophic response to pressure overload, whereas adipose triglyceride lipase overexpression is protective. 145, 146 In opposition to the hypertrophic heart, the diabetic heart shows increased triacylglyceride turnover. 147 This may explain some of the upregulation of PPARα activity and downstream targets observed in this model. What is striking, however, is that these 2 different models both show increased ceramide content, indicating a mismatch between fatty acid uptake, triacylglyceride turnover, PPARα activation.
Conclusions
The past 2 decades have witnessed dramatic changes in the perception of cardiac metabolism. Here, we have drawn attention to a new understanding of mitochondrial physiology beyond the synthesis of ATP, to the importance of metabolic signals in the adaptive and maladaptive responses of the heart to a variety of environmental changes, to the importance of the turnover of endogenous substrates (eg, triacylglycerides), and to the importance of moiety conserved cycles for the efficient transfer of energy in the context of metabolic flexibility. Our review is far from a complete presentation of cardiac metabolism. Yet, we hope it offers new impulses for further investigations.
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